AOAC SMPR 2014.011: Determination of phosphodiesterase type 5 (PDE5) inhibitors in dietary ingredients and supplements

被引:0
|
作者
Mastovska, Katerina [1 ]
Arora, Saurabh [2 ]
Betz, Joseph [3 ]
Bzhelyansky, Anton [4 ]
Cain, Teresa [5 ]
Chlenov, Anatoly [6 ]
Edwards, John [7 ]
Giancaspro, Gabriel [4 ]
Hildreth, Jana [8 ]
Ingle, Prashant [9 ]
Kennedy, David [10 ]
Koch, Todd [11 ]
Krynitsky, Alexander [5 ]
Lock, Stephen [12 ]
Neal-Kababick, James [13 ]
Nickum, Elisa [5 ]
Phillips, Melissa [14 ]
Rimmer, Catherine [14 ]
Royce, Steve [15 ]
Schaneberg, Brian [16 ]
Shimelis, Olga [17 ]
Sullivan, Darryl [1 ]
Travis, John [18 ]
Vaclavik, Lukas [1 ]
Yu, Kate [19 ]
Zielinski, Garrett [1 ]
Zweigenbaum, Jerry [15 ]
Coates, Scott [20 ]
机构
[1] Covance Laboratories, United States
[2] Auriga Research Ltd., United States
[3] NIH, ODS, United States
[4] U.S. Pharmacopeia, United States
[5] U.S. Food and Drug Administration, CFSAN, United States
[6] PerkinElmer, United States
[7] Process NMR Assos, United States
[8] Synutra Pure, United States
[9] Herbalife, United States
[10] Phenomenex, United States
[11] Pfizer Consumer Healthcare, United States
[12] AB SCIEX, United States
[13] Flora Research Laboratories, United States
[14] NIST, United States
[15] Agilent Technologies, Inc., United States
[16] Starbucks Coffee Co., United States
[17] SUPELCO, Sigma-Aldrich, United States
[18] NSF International, United States
[19] Waters Corp., United States
[20] AOAC INTERNATIONAL, United States
关键词
D O I
10.5740/jaoac.int.SMPR2014.011
中图分类号
学科分类号
摘要
引用
收藏
页码:1064 / 1067
相关论文
共 50 条
  • [1] Identification of phosphodiesterase type 5 (PDE5) Inhibitors in dietary ingredients and supplements
    20163502760897
    1600, AOAC International (98):
  • [3] Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
    Gheorghiu, Oana Ramona Catalina
    Ciobanu, Anne Marie
    Gutu, Claudia Maria
    Chitescu, Carmen Lidia
    Costea, Giorgiana Valentina
    Anghel, Daniela Madalina
    Vlasceanu, Ana Maria
    Baconi, Daniela Luiza
    MOLECULES, 2023, 28 (10):
  • [4] Comparison of phosphodiesterase type 5 (PDE5) inhibitors
    Wright, P. J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 967 - 975
  • [5] Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
    Dorsey, Philip
    Keel, Christopher
    Klavens, Meghan
    Hellstrom, Wayne J. G.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (07) : 1109 - 1122
  • [6] Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements
    Nguyen, Thi Oanh
    Tran, Cao-Son
    Do, Thi Thu Hang
    Nguyen, Thi Minh Hoa
    Bui, Quang-Dong
    Bui, Cao-Tien
    Nguyen, Hong-Ngoc
    Dang, Thu-Hien
    Dinh, Viet-Chien
    Nguyen, Thi Anh Huong
    Le, Thi Hong Hao
    JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY, 2021, 2021
  • [7] Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors
    Blount, Mitsi A.
    Zoraghi, Roya
    Bessay, Emmanuel P.
    Beasley, Alfreda
    Francis, Sharron H.
    Corbin, Jackie D.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02): : 730 - 737
  • [8] Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach
    Ongaro, Alberto
    Zagotto, Giuseppe
    Memo, Maurizio
    Gianoncelli, Alessandra
    Ribaudo, Giovanni
    NATURAL PRODUCT RESEARCH, 2021, 35 (10) : 1648 - 1653
  • [9] A review of synthetic phosphodiesterase type 5 inhibitors (PDE-5i) found as adulterants in dietary supplements
    Kee, Chee-Leong
    Ge, Xiaowei
    Gilard, Veronique
    Malet-Martino, Myriam
    Low, Min-Yong
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2018, 147 : 250 - 277
  • [10] Phosphodiesterase type 5 (PDE5) inhibition and cognitive enhancement
    Devan, BD
    Duffy, KB
    Bowker, JL
    Bharati, IS
    Nelson, CM
    Daffin, LW
    Spangler, EL
    Ingram, DK
    DRUGS OF THE FUTURE, 2005, 30 (07) : 725 - 736